Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3422]

Iberdomide in combination with dexamethasone for multiple myeloma

Prof Sagar Lonial - Winship Cancer Institute, Atlanta, USA

Iberdomide in combination with dexamethasone for multiple myeloma ( Prof Sagar Lonial - Winship Cancer Institute, Atlanta, USA )

First results of the GMMG-CONCEPT trial for multiple myeloma

Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg...

First results of the GMMG-CONCEPT trial for multiple myeloma ( Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, Germany )

Once-weekly carfilzomib combined with lenalidomide and dexamethasone for...

Prof David Siegel - John Theurer Cancer Center at Hackensack University Medical...

Once-weekly carfilzomib combined with lenalidomide and dexamethasone for multiple myeloma ( Prof David Siegel - John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, USA )

Ruxolitinib, lenalidomide and methylprednisolone for relapsed/refractory...

Dr James Berenson - Oncotherapeutics, West Hollywood, USA

$Ruxolitinib, lenalidomide and methylprednisolone for relapsed/refractory multiple myeloma ( Dr James Berenson - Oncotherapeutics, West Hollywood, USA )$

Treatment options for high risk relapsed/refractory multiple myeloma

Dr James Berenson - Oncotherapeutics, West Hollywood, USA

$Treatment options for high risk relapsed/refractory multiple myeloma ( Dr James Berenson - Oncotherapeutics, West Hollywood, USA )$

BCMA: A new biomarker for multiple myeloma

Dr James Berenson - Oncotherapeutics, West Hollywood, USA

BCMA: A new biomarker for multiple myeloma ( Dr James Berenson - Oncotherapeutics, West Hollywood, USA )

ICARIA: Isatuximab, pomalidomide and dexamethasone in relapsed/refractory...

Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia

$ICARIA: Isatuximab, pomalidomide and dexamethasone in relapsed/refractory multiple myeloma ( Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia )$

BELLINI: Venetoclax or placebo with bortezomib and dexamethasone for relapsed...

Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia

$BELLINI: Venetoclax or placebo with bortezomib and dexamethasone for relapsed/refractory multiple myeloma ( Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia )$

New standard of care for lung cancer patients with EGFR mutations

Dr Gelenis Domingo - Memorial Healthcare System, Hollywood, FL, USA

New standard of care for lung cancer patients with EGFR mutations ( Dr Gelenis Domingo - Memorial Healthcare System, Hollywood, FL, USA )

Evaluating treatment options for acute myeloid leukaemia

Dr Amanda Brahim - Memorial Healthcare System, Hollywood, FL, USA

Evaluating treatment options for acute myeloid leukaemia ( Dr Amanda Brahim - Memorial Healthcare System, Hollywood, FL, USA )

Recent advances in smouldering and relapsed or refractory multiple myeloma

Dr Jose Sandoval - Moffitt Cancer Center, Tampa, USA

$Recent advances in smouldering and relapsed or refractory multiple myeloma ( Dr Jose Sandoval - Moffitt Cancer Center, Tampa, USA )$

Latest updates in HER2-positive metastatic breast cancer: The NALA and SOPHIA...

Dr Connie Guaqueta - Memorial Cancer Institute, Miami, USA

Latest updates in HER2-positive metastatic breast cancer: The NALA and SOPHIA trials ( Dr Connie Guaqueta - Memorial Cancer Institute, Miami, USA )

More from ecancer